The health authorities in the United States revealed a revolutionary treatment for vitiligo in adults and children, which may be the first of its kind to treat this disease that affects millions globally, according to the “Sky News Arabia” network, and the US Food and Drug Administration granted approval for the “Opzelura” cream produced by the company InSights, as a topical treatment for non-articular vitiligo in adults and children aged 12 years and over.
With this great scientific development, Obzilora cream became the first treatment for re-pigmentation of the skin of patients with vitiligo to receive approval from the Food and Drug Administration, according to the “Pharmaceutical Industries” website.
How to use it
In patients with non-articular vitiligo, the new cream is approved to be used topically and continuously on non-pigmented patches of skin, twice a day, and should not be used on more than 10 percent of the body surface area, and the company noted that the patient’s response to treatment may require the application of the cream Upzilora for more than 24 weeks.
Experiments were conducted on more than 600 people with non-articular vitiligo, aged 12 years or older, and according to the results at week 24, nearly 30% of the people who received the new cream achieved an improvement in their skin color by at least 75% in the areas of vitiligo.
Insights CEO Herve Hopinot said: “Getting approval to use the Obzelura treatment, our company offers treatment to patients with high medical needs, who have not previously had approved treatments.”
It is reported that vitiligo affects people of all skin types, although it is more pronounced in people with dark skin.
According to estimates, vitiligo affects 1 to 2 percent of the world’s population, and it is not a fatal or contagious disease.